Last reviewed · How we verify
CB-183,315
CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome.
CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome. Used for Gram-positive bacterial infections (phase 3 development).
At a glance
| Generic name | CB-183,315 |
|---|---|
| Also known as | Surotomycin |
| Sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | Bacterial protein synthesis inhibitor |
| Target | Bacterial ribosome |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CB-183,315 inhibits bacterial protein synthesis through a novel mechanism of action targeting gram-positive bacteria. The drug is designed to overcome resistance mechanisms seen with existing antibiotics. It represents a new class of antibacterial agents developed to address unmet needs in serious gram-positive infections.
Approved indications
- Gram-positive bacterial infections (phase 3 development)